Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray…
Articles by Andrea Lobo, PhD
The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry,…
Certain clinical attributes of disease-modifying therapies (DMTs), such as safety and the medication’s impact on risk of relapse and disability…
Supplementation with coconut oil and the green tea component epigallocatechin gallate (EGCG) significantly reduces the levels of fatty molecules called…
A commercial probiotic supplement containing the yeast Saccharomyces boulardii significantly eased pain and fatigue, and improved mental health and quality…
A test called Elecsys NfL — developed by Roche to measure blood levels of the nerve damage biomarker neurofilament…
A Phase 1 clinical trial evaluating LPX-TI641, Lapix Therapeutics‘ experimental therapy for multiple sclerosis (MS) and other autoimmune…
More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the…
The Accelerated Cure Project for Multiple Sclerosis and the Arab Board for Clinical Research have partnered with the Association…
Heligenics has discovered a number of variations in the interferon beta 1 (IFNB1) gene that may markedly improve the…
Tiziana Life Sciences has started to recruit clinical sites for a Phase 2a clinical trial that will investigate its…
The European Commission has approved Tyruko (natalizumab), the first biosimilar of Tysabri, for the treatment of adults with…
Anokion has finished enrolling patients in the second part of its Phase 1 clinical trial investigating ANK-700 for…
Imcyse has completed patient enrollment and initial dosing in a Phase 1 clinical trial evaluating IMCY-0141, its next-generation immunotherapy,…
Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple…
Octave Bioscience was selected as a finalist in this year’s Innovation by Design Awards in recognition of the platform…
Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS)…
Neuro Night, a philanthropic event set for October in Scottsdale, Arizona, is raising funds for the Barrow Neurological Institute…
Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced…
A web-based wellness intervention program that educated multiple sclerosis (MS) patients on dietary plans, stress management, sleep, and exercise…
People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of…
Icometrix‘s quantification software for brain MRI scans has received a Current Procedural Terminology (CPT) III code, a temporary code…
The director of the Multiple Sclerosis Center of Catalonia (CEMCAT) has been recognized with the 2023 Charcot Award, a…
A microRNA called miR-548a-3p, a small molecule important for regulation of gene activity, may help to identify people with…
As part of last week’s World MS Day, a documentary about the life of Mathew Embry, a multiple sclerosis…
In an effort to improve access to medical care for all people with multiple sclerosis (MS), the Consortium…
Monte Rosa Therapeutics has selected MRT-6160, its second candidate for development, for treating multiple sclerosis (MS) and several…
Long-term treatment with Ocrevus (ocrelizumab) doesn’t change the diversity of T-cells — those needed to mount effective immune responses…
LAPIX Therapeutics has secured a new U.S. patent covering the use of its experimental oral therapy LPX-TI641 as a…
Genentech‘s investigational BTK inhibitor fenebrutinib significantly reduced the number of new brain lesions and showed no new safety…